Search Immortality Topics:

Page 20«..10..19202122..3040..»


Immutep Granted European Patent for IMP761

Posted: October 21, 2020 at 11:35 am

SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled “Anti-LAG-3 Antibodies” by the European Patent Office.

Original post:
Immutep Granted European Patent for IMP761

Recommendation and review posted by Fredricko

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy…

Posted: October 21, 2020 at 11:35 am

See original here:
Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy...

Recommendation and review posted by Fredricko

Radius Health, Inc.: Progress Since May 2020

Posted: October 21, 2020 at 11:35 am

WALTHAM, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020. The Company will provide further updates during its third quarter earnings call and at subsequent investor conferences. The key areas of activity included as part of its update are outlined below.

Original post:
Radius Health, Inc.: Progress Since May 2020

Recommendation and review posted by Fredricko

SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020

Posted: October 21, 2020 at 11:35 am

Three posters highlight the potential for ibrexafungerp use in treating and preventing serious fungal infections Three posters highlight the potential for ibrexafungerp use in treating and preventing serious fungal infections

Read the original post:
SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020

Recommendation and review posted by Fredricko

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids

Posted: October 21, 2020 at 11:35 am

BASEL, Switzerland, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis and in women with uterine fibroids. The data were presented in virtual oral and poster sessions during the American Society for Reproductive Medicine (ASRM) 2020 Virtual Congress, held October 17-21, 2020.

See the original post here:
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids

Recommendation and review posted by Fredricko

The Quest for Blockbuster Drugs Continues

Posted: October 21, 2020 at 11:35 am

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire — 180 Life Sciences Corp. today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

Continued here:
The Quest for Blockbuster Drugs Continues

Recommendation and review posted by Fredricko


Page 20«..10..19202122..3040..»